Cingulate Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $71.1M
- Price
- $4.89
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.95%
- Volume
- 111.7K
About
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
Quick stats
Shares outstanding14.5M
Computed float8.9M
Float / shares60.9%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001862150
Websitehttps://www.cingulate.com
AI Summary
AI-generated1/10
minorneutralother
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
Cingulate Chairman and CEO Shane Schaffer and Chief Commercial Officer Bryan Downey will participate in two sessions at the Indegene Digital Summit on September 22, 2026, at the National Constitution Center in Philadelphia.
Schaffer joins 'The SMART Launch' panel on how emerging pharma companies can retain ownership and strategic control of their assets while accessing external partner capabilities, positioning it as a more capital-efficient alternative to building large internal commercial infrastructure or licensing assets to larger drugmakers.
The appearance comes as Cingulate prepares for potential commercialization of its lead ADHD asset CTx-1301; the FDA issued a Complete Response Letter for the NDA on June 1, 2026, and the company says it is completing requested CMC work and plans to resubmit, though timing is not assured.
Cingulate sizes the US ADHD market at roughly 100 million annual prescriptions, with over 20 million diagnosed patients, and notes adult ADHD prevalence is larger and growing faster than child and adolescent segments combined.
Red flags
- FDA issued a Complete Response Letter for the CTx-1301 NDA on June 1, 2026 (after the May 31, 2026 PDUFA date); resubmission timing and approval are not assured
- Forward-looking statements explicitly reference anticipated capital needs and financing plans — dilution/financing risk for a pre-revenue biotech
- No new clinical, regulatory, or financial data in this release; conference participation is promotional